Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19089364 | 0.86 | EGFR (0.52) | EGFRERBB2ABL1BCRJAK3 | |
| SCHEMBL19089296 | 0.79 | EGFR (0.53) | EGFRJAK3BTK | |
| SCHEMBL19089585 | 0.77 | EGFR (0.56) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL19089584 | 0.77 | EGFR (0.52) | EGFRERBB2KDREPHA2EPHB4 | |
| SCHEMBL6484196 | 0.69 | JAK3 (0.65) | EGFRERBB2ABL1BCRJAK3 | |
| SCHEMBL21980696 | 0.68 | EGFR (0.48) | EGFRERBB2JAK3BTKKDR | |
| SCHEMBL30213748 | 0.68 | EGFR (0.62) | EGFRERBB2 | |
| SCHEMBL30213663 | 0.68 | EGFR (0.61) | EGFRERBB2 | |
| SCHEMBL19089368 | 0.67 | EGFR (0.61) | EGFR | |
| SCHEMBL20548844 | 0.66 | EGFR (0.60) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | EGFR 1/4885ERBB2 4/4885ABL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.